Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn R Webster

Showing results (61-70 of 131) with videos related to

Pageof 14
Sort By:
Current Medical Research and Opinion|January 26, 2018
Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tabletsLynn R Webster, Eugene R Viscusi, Colville Brown, et al.
Journal of Pain Research|April 14, 2020
A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid TherapyLynn R Webster, Martin E Hale, Tadaaki Yamada, et al.
Advances in Therapy|May 9, 2019
Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized StudyLynn R Webster, Eric R Kinzler, Carmela Pantaleon, et al.
Postgraduate Medicine|September 10, 2011
Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsulesLynn R Webster, Randall Brewer, David Morris, et al.
The American Journal of Gastroenterology|April 29, 2015
A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer painM Mazen Jamal, Atoya B Adams, Jan-Peter Jansen, et al.
Pain Medicine (Malden, Mass.)|March 28, 2008
Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic painLynn R Webster, Keri L Fakata, Steven Charapata, et al.
Substance Abuse and Rehabilitation|January 30, 2014
Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid usersLynn R Webster, Robert L Rolleri, Glenn C Pixton, et al.
Drugs in R&D|September 10, 2011
Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid usersLynn R Webster, Franklin K Johnson, Joseph Stauffer, et al.
Pain Medicine (Malden, Mass.)|January 28, 2016
A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneLynn R Webster, Ernest A Kopecky, Michael D Smith, et al.
Journal of Opioid Management|January 9, 2018
Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioidsChristopher J Miller, Richard C Dart, Nathaniel P Katz, et al.
Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
Current Medical Research and Opinion|January 26, 2018
Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tabletsLynn R Webster, Eugene R Viscusi, Colville Brown, et al.
Journal of Pain Research|April 14, 2020
A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid TherapyLynn R Webster, Martin E Hale, Tadaaki Yamada, et al.
Advances in Therapy|May 9, 2019
Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized StudyLynn R Webster, Eric R Kinzler, Carmela Pantaleon, et al.
Postgraduate Medicine|September 10, 2011
Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsulesLynn R Webster, Randall Brewer, David Morris, et al.
The American Journal of Gastroenterology|April 29, 2015
A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer painM Mazen Jamal, Atoya B Adams, Jan-Peter Jansen, et al.
Pain Medicine (Malden, Mass.)|March 28, 2008
Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic painLynn R Webster, Keri L Fakata, Steven Charapata, et al.
Substance Abuse and Rehabilitation|January 30, 2014
Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid usersLynn R Webster, Robert L Rolleri, Glenn C Pixton, et al.
Drugs in R&D|September 10, 2011
Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid usersLynn R Webster, Franklin K Johnson, Joseph Stauffer, et al.
Pain Medicine (Malden, Mass.)|January 28, 2016
A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneLynn R Webster, Ernest A Kopecky, Michael D Smith, et al.
Journal of Opioid Management|January 9, 2018
Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioidsChristopher J Miller, Richard C Dart, Nathaniel P Katz, et al.
Pageof 14